drugset
drugset / Trial / NCT00040950

Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00040950 ↗

Phase 1 Completed Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) · collab
Treatment

Summary

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Biological therapies such as CpG 7909 use different ways to stimulate the immune system and stop cancer cells from growing. Combining CpG 7909 with rituximab may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of CpG 7909 plus rituximab in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.

Timeline

Start
2002-03
Primary completion
—
Completion
2007-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject agatolimod Oligonucleotide (other) 0.01 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.04 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.08 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.16 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.24 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.32 mg/kg Intravenous
Subject agatolimod Oligonucleotide (other) 0.48 mg/kg Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

lymphoma